OKYO Pharma LTD

Contributing Author

Recent Articles by OKYO Pharma LTD

Jul-08	OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain OKYO -5.14% GlobeNewswire
Jul-07	OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium OKYO +8.70% GlobeNewswire
May-19	OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD OKYO GlobeNewswire
Apr-29	OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May OKYO GlobeNewswire
Apr-07	OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting OKYO GlobeNewswire
Mar-19	OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO GlobeNewswire
Mar-19	OKYO Pharma Announces Director Acquires Shares OKYO GlobeNewswire
Mar-19	OKYO Pharma Announces Chief Development Officer and Director Acquires Shares OKYO GlobeNewswire
Mar-18	OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain OKYO GlobeNewswire
Feb-23	OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress OKYO GlobeNewswire
Feb-12	OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares OKYO -19.35% GlobeNewswire
Feb-12	OKYO Pharma Announces Public Offering of Ordinary Shares OKYO +11.28% OKYO -19.35% GlobeNewswire
Feb-11	OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners OKYO -6.70% GlobeNewswire
Feb-10	OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer OKYO +5.03% GlobeNewswire
Jan-30	OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting OKYO GlobeNewswire
Jan-28	OKYO Pharma Announces Successful Type C Meeting with the FDA OKYO GlobeNewswire
Jan-23	FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain OKYO -6.33% GlobeNewswire
Jan-05	OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer OKYO +7.62% GlobeNewswire
Dec-19	OKYO Pharma to Ring the Opening Bell at Nasdaq OKYO +8.56% GlobeNewswire
Dec-15	OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO -8.25% GlobeNewswire
Dec-11	OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain OKYO +6.93% GlobeNewswire
Dec-03	OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO -5.77% GlobeNewswire
Nov-21	OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO +10.99% GlobeNewswire
Nov-18	OKYO Pharma to Present at OIS XV in San Diego OKYO GlobeNewswire
Oct-29	OKYO Pharma to Present at BIO-Europe 2025 in Vienna OKYO +6.67% GlobeNewswire
Oct-16	OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO GlobeNewswire
Sep-22	OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain OKYO +13.64% GlobeNewswire
Jul-17	OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain OKYO GlobeNewswire
Jul-16	OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain OKYO +7.64% GlobeNewswire
Jun-11	OKYO Pharma to Present at the Bio International Convention OKYO +12.56% GlobeNewswire
May-19	OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit OKYO +7.91% GlobeNewswire

OKYO Pharma LTD

Recent Articles by OKYO Pharma LTD

Upgrade your Finviz experience